Reviva Pharmaceuticals Holdings (RVPH) Net Income (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Net Income of -$3.2 million for Q1 2026, up 7.06% sequentially from -$3.4 million in Q4 2025, and up 50.32% YoY from -$2.1 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Net Income (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Net Income for 9 years, with the latest figure at -$3.2 million in Q1 2026.
- Quarterly Net Income rose 50.32% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.7 million (down 1895.73% YoY) and the FY2025 annual result came in at -$19.9 million, down 28041.71% from the prior year.
- Net Income grew to -$3.2 million in Q1 2026 per RVPH's latest filing, from -$3.4 million in the prior quarter.
- Over five years, Net Income peaked at $23.6 million in Q4 2024 and troughed at -$12.0 million in Q4 2022.
- A 5-year average of -$5.3 million and a median of -$6.9 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income tumbled 675.84% in 2022, then jumped 353.52% in 2024.
- Over 5 years, Net Income stood at -$12.0 million in 2022, then rose by 22.62% to -$9.3 million in 2023, then surged by 353.52% to $23.6 million in 2024, then plunged by 114.58% to -$3.4 million in 2025, then gained by 7.06% to -$3.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$3.2 million, -$3.4 million, and -$4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | -2.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.45 Mn |
| Mar 31, 2026 | -3.20 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Sep 30, 2025 | -4.01 Mn |
| Jun 30, 2025 | -6.05 Mn |
| Mar 31, 2025 | -6.43 Mn |
| Dec 31, 2024 | 23.59 Mn |
| Sep 30, 2024 | -8.37 Mn |
| Jun 30, 2024 | -7.86 Mn |
| Mar 31, 2024 | -7.43 Mn |
| Dec 31, 2023 | -9.30 Mn |
| Sep 30, 2023 | -11.35 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Mar 31, 2023 | -6.85 Mn |
| Dec 31, 2022 | -12.02 Mn |
| Sep 30, 2022 | -3.52 Mn |
| Jun 30, 2022 | -5.34 Mn |
| Mar 31, 2022 | -7.37 Mn |
| Dec 13, 2021 | -3.68 Mn |
| Sep 30, 2021 | -2.28 Mn |